The London Medicines Evaluation Network has published a briefing sheet that aims to support prescribers by providing answers to commonly asked questions about the introduction of these medicines.
There are two infliximab biosimilars now licensed and available in the UK – Inflectra® and Remsima®. Both are the same biosimilar product (CT-P13; manufactured by Celltrion), with the same indications, dosing regimen, pharmaceutical form and strength as the reference medicine Remicade®.